138 related articles for article (PubMed ID: 29903759)
1. L-leucine increases translation of
Bello E; Kerry J; Singh S; Yip BH; Kušec R; Killick S; Raynaud S; Boultwood J; Pellagatti A
Haematologica; 2018 Nov; 103(11):e496-e500. PubMed ID: 29903759
[No Abstract] [Full Text] [Related]
2. Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH; Pellagatti A; Vuppusetty C; Giagounidis A; Germing U; Lamikanra AA; Roberts DJ; Fernandez-Mercado M; McDonald EJ; Killick S; Wainscoat JS; Boultwood J
Leukemia; 2012 Sep; 26(9):2154-8. PubMed ID: 22430631
[No Abstract] [Full Text] [Related]
3. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
4. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
Boultwood J; Yip BH; Vuppusetty C; Pellagatti A; Wainscoat JS
Adv Biol Regul; 2013 Jan; 53(1):8-17. PubMed ID: 23031788
[TBL] [Abstract][Full Text] [Related]
5. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
Yip BH; Vuppusetty C; Attwood M; Giagounidis A; Germing U; Lamikanra AA; Roberts DJ; Maciejewski JP; Vandenberghe P; Mecucci C; Wainscoat JS; Pellagatti A; Boultwood J
Leukemia; 2013 Aug; 27(8):1760-3. PubMed ID: 23337929
[No Abstract] [Full Text] [Related]
6. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
Pellagatti A; Hellström-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
Br J Haematol; 2008 Jul; 142(1):57-64. PubMed ID: 18477045
[TBL] [Abstract][Full Text] [Related]
7. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.
Payne EM; Virgilio M; Narla A; Sun H; Levine M; Paw BH; Berliner N; Look AT; Ebert BL; Khanna-Gupta A
Blood; 2012 Sep; 120(11):2214-24. PubMed ID: 22734070
[TBL] [Abstract][Full Text] [Related]
8. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
9. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
11. [Ribosomal protein in impaired erythropoiesis: Diamond-Blackfan anemia and 5q- syndrome].
Ito E
Rinsho Ketsueki; 2009 Oct; 50(10):1539-47. PubMed ID: 19915364
[No Abstract] [Full Text] [Related]
12. Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival.
Czibere A; Bruns I; Junge B; Singh R; Kobbe G; Haas R; Germing U
Haematologica; 2009 Oct; 94(10):1453-5. PubMed ID: 19794090
[TBL] [Abstract][Full Text] [Related]
13. Autogenous Control of 5′TOP mRNA Stability by 40S Ribosomes.
Gentilella A; Morón-Duran FD; Fuentes P; Zweig-Rocha G; Riaño-Canalias F; Pelletier J; Ruiz M; Turón G; Castaño J; Tauler A; Bueno C; Menéndez P; Kozma SC; Thomas G
Mol Cell; 2017 Jul; 67(1):55-70.e4. PubMed ID: 28673543
[TBL] [Abstract][Full Text] [Related]
14. Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.
Garderet L; Kobari L; Mazurier C; De Witte C; Giarratana MC; Pérot C; Gorin NC; Lapillonne H; Douay L
Haematologica; 2010 Mar; 95(3):398-405. PubMed ID: 19815832
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome associated with isolated del (5q) chromosome abnormality ("5q- syndrome").
Maslak P
Blood; 2007 Dec; 110(12):3825. PubMed ID: 18062093
[No Abstract] [Full Text] [Related]
16. MDS with isolated del(5q) and internuclear bridging.
Xu Z; McGowan-Jordan J
Blood; 2017 Apr; 129(16):2333. PubMed ID: 28428239
[No Abstract] [Full Text] [Related]
17. [Apropos of the case "Erythroblastopenia associated with myelodysplastic syndrome"].
Aventín A
Sangre (Barc); 1996 Dec; 41(6):483. PubMed ID: 9148428
[No Abstract] [Full Text] [Related]
18. Chromosomal instability and telomere shortening in long-term culture of hematopoietic stem cells: insights from a cell culture model of RPS14 haploinsufficiency.
Thomay K; Schienke A; Vajen B; Modlich U; Schambach A; Hofmann W; Schlegelberger B; Göhring G
Cytogenet Genome Res; 2014; 142(1):14-20. PubMed ID: 24192547
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.
Steensma DP; Ebert BL
Blood; 2013 May; 121(21):4428. PubMed ID: 23704049
[No Abstract] [Full Text] [Related]
20. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
